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Psoriasis has been associated with other autoimmune diseases, e.g. inflammatory bowel disease and 
autoimmune thyroid disease.1 These diseases may share genetic susceptibility loci and autoimmune 
mechanisms including interleukin-17-dependent pathways.2-4  However, the relationship between 
psoriasis and autoimmune thyroid disease remains unclear and a recent meta-analysis of available 
evidence concluded that more data are needed.5 Therefore, we examined thyroid function in a 
population-based sample of psoriasis patients. 
 
Thyroid function was assessed in non-fasting blood samples from 21,186 subjects >20 years who 
participated in the Danish General Suburban Population Study6 including 1173 (5.5%) with self-
reported psoriasis determined by an affirmative response to the question ‘Do you suffer from or 
have you suffered from psoriasis?’. Plasma levels of thyroid-stimulating hormone (TSH), free 
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thyroxine (fT4), total triiodothyronine (tT3), and thyroid peroxidase antibodies (TPO-Abs) were 
measured with immunoassays (Cobas 6000 analyzer [Roche, Basel, Switzerland] and Brahms Kryptor 
[Hennigsdorf, Germany]). TPO-Ab levels greater than 60 U/mL were considered positive. Self-
reported information included use of medication for hyper- or hypothyroidism, and answer (yes or 
no) to the statement that ‘according to my general practitioner (GP), I suffer from hyperthyroidism 
or hypothyroidism’. Subclinical hyperthyroidism and hypothyroidism were defined as TSH<0.4 mIU/L 
and TSH>3.8 mIU/L, respectively, with normal fT4 and tT3 levels, in absence of self-reported use of 
thyroid medication or GP diagnosis of hyper- or hypothyroidism. Clinical hyperthyroidism was 
defined as TSH<0.4 mIU/L and increased fT4 and/or tT3 levels, self-reported use of medication for 
hyperthyroidism and/or a GP diagnosis of hereof. Clinical hypothyroidism was defined as TSH>3.8 
mIU/L and decreased fT4 and/or tT3 levels, self-reported use of medication for hypothyroidism 
and/or a GP diagnosis hereof. Patients with psoriasis (n=1,127 due to missing data on smoking 
[n=40] and body mass index [BMI, n=6]) were matched 1:5 for sex, age, BMI, and smoking with 
controls (n=5,635) without the disease.  The study was approved by the regional ethical committee 
(SJ-113, SJ-114, SJ-191) and the Danish Data Protection Agency. 
 
Characteristics of the two groups are shown in Table 1. Patients with psoriasis had increased levels 
of tT3 (1.69±0.32 vs. 1.72±0.33 nmol/L; p=0.01). Further adjustment for use of contraceptive pills, 
lipid levels, albumin, and high sensitive C-reactive protein, respectively, did not considerably change 
this result. Levels of TSH, fT4 and TPO-Abs were similar and percentages of subjects with TPO-Ab 
positivity, self-reported use of medication for hyper- or hypothyroidism, self-reported GP diagnosis 
hereof, and clinical and subclinical hyper- or hypothyroidism, respectively, were not significantly 
different between the two groups. 
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In this study, self-reported psoriasis was linked with increased levels of tT3 but not with TPO-Ab 
positivity and clinical or subclinical thyroid dysfunction. Mechanisms underlying increased tT3 (with 
normal fT4 and TSH), and its significance in subjects with psoriasis remain to be determined. To our 
knowledge, the results represent the largest reported data on thyroid function in psoriasis and are in 
line with recent results from individuals with psoriasis (n=173) in the population-based Rotterdam 
study where no changes of TSH and fT4, and TPO-Ab positivity was found.5 In that report, T3 was not 
measured and an accompanying meta-analysis suggested that TPO-Ab positivity and hyper- or 
hypothyroidism may be associated with psoriasis, albeit that studies were heterogeneous, e.g. with 
different definitions of psoriasis/psoriatic arthritis and/or thyroid dysfunction.5, 7, 8 Limitations of our 
study include that psoriasis was self-reported (leaving room for recall bias and information bias), 
psoriasis severity and treatment were not assessed, and other thyroid function tests, e.g. free T3 and 
reverse T3 levels were not measured. The results indicate that on a population scale psoriasis may 
be linked with increased levels of tT3 and more studies of thyroid function in psoriasis are 
warranted. 
 
References 
1. Hsu LN, Armstrong AW. Psoriasis and autoimmune diseases: A review of the literature. J Am Acad 
Dermatol 2012; 67: 1076-9. 
2. Corsapas C, Voight BF, Rossin E et al. Pervasive sharing of genetic effects in autoimmne disease. 
PLOS Genet 2011;7 (8): e1002254. Doi: 10.1371/journal.pgen.1002254. 
3. Bedoya SK, Lam B, Lau K et al. Th17 cells in immunity and autoimmunity. Clin Dev Immunol 2013; 
2013: 986789. doi: 10.1155/2013/986789. 
4. Li D, Cai VV, Gu R, Zhang Y et al. Th17 cell plays a role in the pathogenesis of Hashimoto’s 
thyroiditis in patients. Clin Immunol 2013; 149: 411-20. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
5. Khan SR, Bano A, Wakkee M et al. The association of autoimmune thyroid disease: a prospective 
cohort study, systematic review and meta-analysis. Eur J Endocrinol 2017; 177: 347-59. 
6. Bergholdt HK, Bathum L, Kvetny J et al. Study design, participation and characteristics of the 
Danish Suburban Population Study. Dan Med J 2013; 60: A4693. 
7. Antonilli A, Delle Sedie A, Fallahi P et al. High prevalence of thyroid autoimmunity and 
hypothyroidism in patients with psoriatic arthritis. J Rheumatol 2006; 33: 2026-8. 
8. Peluso R, Lupoli GA, Del Puentes A et al. Prevalence of thyroid autoimmunity in patients with 
spondylarthropathies. J Rheumatol 2011; 38: 1371-7.  
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1. Clinical characteristics of the psoriasis and the matched comparison group. 
 Psoriasis 
(n=1,127) 
Comparison group 
(n=5,635) 
p 
Age, years 56.9±12.2 56.9±13.5 0.91* 
Males, % (n) 45.1 (508) 45.1 (2540) 1.00* 
BMI, kg/m2 27.2±5.0 27.2±4.8 0.71* 
TSH, mIU/L  2.09±1.70 2.11±2.33 0.83 
Total T3, nmol/L 1.72±0.33 1.69±0.32 0.01 
Free T4, pmol/L 15.65±2.38 15.60±2.29 0.49 
TPO-Abs, U/mL (median [IQR]) 19 [12;29] 20 [14;28] 0.16# 
TPO-Abs> 60 U/mL, % (n) 11.8 (66) 12.8 (533) 0.57 
Medication for hyperthyroidism, % (n) 
Medication for hypothyroidism, % (n) 
1.4 (16) 
5.0 (55) 
1.1 (59) 
4.4 (243) 
0.43 
0.34 
GP diagnosis of hyperthyroidism, % (n) 
GP diagnosis of hypothyroidism, % (n) 
2.6 (28) 
6.2 (67) 
2.3 (125) 
5.3 (289) 
0.64 
0.25 
Thyroid status†, % (n)   0.72 
   Clinical hyperthyroidism 
   Subclinical hyperthyroidism 
   Euthyroidism 
   Subclincial hypothyroidism 
   Clinical hypothyroidism 
2.9 (33) 
1.4 (16) 
84.4 (948) 
5.5 (62) 
5.7 (64) 
2.4 (132) 
1.3 (74) 
85.7 (4812) 
5.5 (309) 
5.2 (290) 
hs-CRP, mg/L (median [IQR]) 1.5 (0.8-3.4) 1.5 (0.8-3.2) 0.33# 
Use of oral contraceptives, % (n) 4.4 (49) 4.9 (273) 0.53 
*Populations matched on this parameter, #Statistics performed on logarithm-transformed data, †See 
text. Data are mean±standard deviation unless otherwise indicated. Continuous and categorical 
variables were compared using Student’s t-test and χ2 test, respectively. A larger table including data 
on smoking, blood pressure, lipids, and albumin is available upon request to the corresponding 
author. BMI, body mass index; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating 
hormone; TPO-Abs, thyroid peroxidase antibodies; GP, general practitioner; hs-CRP, high sensitive-C-
reactive protein; IQR, inter-quartile range 
 
 
 
